AstraZeneca's IL-33-targeting antibody tozorakimab has made the grade in two phase 3 chronic obstructive pulmonary disease (COPD) trials, raising the prospects of a class that has recorded some ...

Background The lower airway microbiota in patients with chronic obstructive pulmonary disease (COPD) are likely altered compared with the microbiota in healthy individuals. Information on how the ...

Conclusion People living with COPD are at a significantly heightened risk of CVD over and beyond their predicted risk. This is particularly the case for younger people whose 10-year CVD risk can be ...

Face yoga may improve skin tone and fullness in the mid and lower face. Facial exercises help strengthen facial muscles and maintain fat pad positioning. Consistent practice of face yoga can lead to ...

AstraZeneca’s chronic obstructive pulmonary disease (COPD) candidate has hit the mark in a pair of phase 3 trials, delivering broad efficacy with a mechanism that yielded mixed data for Roche and ...

Clinical benefits of the interleukin-33 inhibitor were observed in a broad population, including both former and current smokers, regardless of eosinophil levels. Topline results were announced from ...

AstraZeneca’s IL-33 blocker, tozorakimab has significantly reduced the annualised rate of COPD exacerbations as an adjuvant to SoC inhaled therapy over placebo in two Phase III studies. Credit: ...

AstraZeneca didn’t release complete data from the trials, called Oberon and Titania, stating that they will be disclosed at an upcoming medical meeting. Those details will be closely watched.

Katya Saturday is all up in arms. But the no-nonsense New Yorker isn’t angry — she’s empowered through sword yoga. And a steel, 30-inch, double-edged blade, named Golden Hour, is her preferred ...

With her bright leotards and soothing, welcoming tone, she helped to demystify a discipline that many Americans in the 1970s viewed as a counterculture practice. Lilias Folan in 1981 on her Cincinnati ...